Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CRLA-4 and Anti-PD-1 Blockade in Rare Tumors) (S1609)
Treatment with Ipilimumab and Nivolumab for Rare Cancers (DART: Dual Anti-CRLA-4 and Anti-PD-1 Blockade in Rare Tumors) (S1609)
Trial Category:
Other Solid Tumor
Contact(s)
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
This study is looking at two specific drugs in a wide range of different tumor types. To get more information, please contact us.
